The FDA's Office of Prescription Drug Promotion says Pacira's promotional materials for Exparel are "extremely concerning," but the drugmaker tells investors the fuss is probably because opioids have been getting a lot of attention lately.
An untitled letter from the FDA's bad-ad unit shows Amarin's triglyceride-lowering medication faced multiple challenges in 2013.
The drug maker, through its venture fund, took a controlling interest in the digital physician marketing firm.
GSK sees a regulatory setback on its once-weekly GLP-1 med, and Spectrum Pharma gets hit with an untitled letter from OPDP on a sales aid for Zevalin.
Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.
Pharmas are spending far less on reprints and far more on digital promotion to physicians and other healthcare professionals, according to a healthcare media buying specialist.
Pharmas spent 40% more on non-personal promotion to healthcare professionals globally last year while continuing to shed sales reps, a Cegedim survey shows.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.